Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylalanine metabolites, attention span and hyperactivity.

K Michals, R Matalon

    The American Journal of Clinical Nutrition
    |August 1, 1985
    PubMed
    Summary

    Phenylalanine metabolites in urine may offer new insights into phenylketonuria (PKU) management. Individual variations suggest current blood phenylalanine level targets may need reevaluation for optimal patient outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

    European journal of clinical nutrition·2017
    Same author

    Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

    European journal of clinical nutrition·2016
    Same author

    Identification of a Novel 14q13.3 Deletion Involving the SLC25A21 Gene Associated with Familial Synpolydactyly.

    Molecular syndromology·2015
    Same author

    Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

    Journal of inherited metabolic disease·2007
    Same author

    Large neutral amino acids in the treatment of phenylketonuria (PKU).

    Journal of inherited metabolic disease·2006
    Same author

    Abnormal expression of genes associated with development and inflammation in the heart of mouse maternal phenylketonuria offspring.

    International journal of immunopathology and pharmacology·2005

    Area of Science:

    • Metabolic disorders
    • Biochemistry
    • Clinical chemistry

    Background:

    • Phenylketonuria (PKU) is a genetic disorder requiring careful management of blood phenylalanine levels.
    • Current PKU treatment guidelines focus on serum phenylalanine concentrations.
    • The neurotoxic potential of phenylalanine metabolites necessitates further investigation.

    Purpose of the Study:

    • To investigate the urinary excretion patterns of phenylalanine metabolites in PKU patients.
    • To explore the correlation between serum phenylalanine levels and urinary metabolite excretion.
    • To assess the potential of phenylalanine metabolites as biomarkers for PKU management and neurotoxicity.

    Main Methods:

    • Urine samples from PKU patients were analyzed for phenylalanine metabolites.
    • Metabolites measured included phenylacetate, phenyllactate, phenylpyruvate, and phenylethylamine.
    • Correlations between serum phenylalanine levels and urinary metabolite excretion were examined.

    Main Results:

    • A general correlation was observed between serum phenylalanine and urinary metabolite excretion.
    • Significant individual variations in metabolite profiles were noted, independent of blood phenylalanine levels.
    • Elevated phenylalanine metabolites were found in urine during PKU pregnancy and in patients with good blood phenylalanine control.

    Conclusions:

    • Current blood phenylalanine level targets in PKU treatment may require reevaluation.
    • Urinary phenylalanine metabolites could serve as novel biomarkers for PKU.
    • These metabolites may provide new parameters for studying PKU's impact on cognitive function and behavior.

    Related Experiment Videos